The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

AstraZeneca reports positive results in Phase 3 lung cancer drug trial

Fri, 7th May 2021 08:32

(Alliance News) - AstraZeneca PLC on Friday said its Imfinzi and tremelimumab drug combination demonstrated an overall survival benefit in a Phase 3 trial as a first-line treatment for patients with mesastatic non-small cell lung cancer.

The results for Imfinzi and tremelimumab combined with chemotherapy showed statistically significant and clinically meaningful benefits to overall survival and progression-free survival, compared to chemotherapy alone.

A trial of Imfinzi with chemotherapy improved progression-free survival, but did not improve overall survival. Each combination demonstrated an acceptable safety profile, AstraZeneca said.

Overall survival measures how long a patient lives after starting a treatment, while progression-free survival measures how long it takes for a cancer to start growing after treatment starts.

Imfinzi is already approved in the US, EU, Japan and other countries for certain types of lung cancer, while tremelimumab has not yet been approved.

"We've seen encouraging uptake of novel combinations in this setting and believe this new approach will add a further option for patients with high unmet medical need. We look forward to discussing next steps with regulatory authorities," Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit, said.

AstraZeneca shares were up 0.6% to 7,724.00 pence in London.

By Ivan Edwards; ivanedwards@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Related Shares

More News

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

IN BRIEF: Hutchmed lung cancer treatment savolitinib approved in China

22 Jun 21 20:16

AstraZeneca's Koselugo gets EU regulatory approval to treat children

AstraZeneca's Koselugo gets EU regulatory approval to treat children

22 Jun 21 09:01

AstraZeneca given EU approval for use of Koselugo in children

(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo drug had been approved for use in children with neurofibromatosis type 1 and plexiform neurofibromas across the European Union.

22 Jun 21 08:25

LONDON MARKET CLOSE: Stocks slide as US Fed still hangs over markets

LONDON MARKET CLOSE: Stocks slide as US Fed still hangs over markets

18 Jun 21 17:04

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.